VBI Vaccines (VBIV) Stock Forecast, Price Target & Predictions
VBIV Stock Forecast
VBI Vaccines stock forecast is as follows: a rating consensus of 'Strong Buy', based on 2 wall street analysts offering a 1-year stock forecast.
VBIV Analyst Ratings
According to 2 Wall Street analysts, VBI Vaccines's rating consensus is 'Strong Buy'. The analyst rating breakdown for VBIV stock is 1 'Strong Buy' (50.00%), 0 'Buy' (0.00%), 1 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 09, 2022 | Raymond James | Strong Buy | Strong Buy | Hold |
| Apr 26, 2022 | Zacks Investment Research | - | Hold | Upgrade |
VBI Vaccines's last stock rating was published by Raymond James on Aug 09, 2022. The company gave VBIV a "Strong Buy" rating, the same as its previous rate.
VBI Vaccines Financial Forecast
VBI Vaccines Revenue Forecast
| Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $485.00K | $293.00K | - | - | $126.00K | $81.00K | $107.00K | $142.00K | $301.00K | $164.00K | $298.00K | $184.00K | $415.00K | $574.00K | $647.00K | $640.00K | $360.00K | $2.68M | $259.00K |
| Avg Forecast | $10.48M | $9.29M | $7.80M | $6.55M | $4.56M | $3.88M | $3.19M | $2.85M | $5.36M | $13.25M | $929.00K | $817.00K | $1.98M | $1.29M | $704.33K | $120.00K | $137.33K | $203.67K | $481.33K | $485.00K | $407.00K | $328.25K | $631.25K | $655.25K | $729.75K | $702.67K | $489.00K | $443.33K | $1.82M | $215.83K |
| High Forecast | $10.48M | $9.29M | $7.80M | $6.55M | $4.56M | $3.88M | $3.19M | $2.85M | $5.36M | $13.25M | $929.00K | $817.00K | $1.98M | $1.29M | $704.33K | $120.00K | $137.33K | $203.67K | $481.33K | $485.00K | $407.00K | $328.25K | $631.25K | $655.25K | $729.75K | $702.67K | $489.00K | $443.33K | $2.19M | $259.00K |
| Low Forecast | $10.48M | $9.29M | $7.80M | $6.55M | $4.56M | $3.88M | $3.19M | $2.85M | $5.36M | $13.25M | $929.00K | $817.00K | $1.98M | $1.29M | $704.33K | $120.00K | $137.33K | $203.67K | $481.33K | $485.00K | $407.00K | $328.25K | $631.25K | $655.25K | $729.75K | $702.67K | $489.00K | $443.33K | $1.46M | $172.66K |
| # Analysts | - | - | - | - | - | - | 1 | - | 1 | - | - | - | - | - | - | - | - | - | - | 6 | 6 | 3 | 3 | 3 | 2 | 2 | 3 | 4 | 7 | 10 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.59% | 0.15% | - | - | 1.05% | 0.59% | 0.53% | 0.30% | 0.62% | 0.40% | 0.91% | 0.29% | 0.63% | 0.79% | 0.92% | 1.31% | 0.81% | 1.47% | 1.20% |
VBI Vaccines's average Quarter revenue forecast for Jul 23 based on 0 analysts is $929.00K, with a low forecast of $929.00K, and a high forecast of $929.00K. VBIV's average Quarter revenue forecast represents a 91.55% increase compared to the company's last Quarter revenue of $485.00K (Mar 23).
VBI Vaccines EBITDA Forecast
| Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | 1 | - | 1 | - | - | - | - | - | - | - | - | - | - | 6 | 6 | 3 | 3 | 3 | 2 | 2 | 3 | 4 | 7 | 10 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | $-18.50M | $-20.27M | - | - | $-15.37M | $-20.34M | $-14.50M | $-15.93M | $-15.06M | $-13.59M | $-11.29M | $-7.60M | $-8.88M | $-3.25M | $-15.60M | $-11.81M | $-13.40M | $-18.27M | $-14.28M |
| Avg Forecast | $-10.48M | $-9.29M | $-7.80M | $-6.55M | $-4.56M | $-3.88M | $-3.19M | $-17.76M | $-5.36M | $-13.25M | $-929.00K | $-18.99M | $-1.98M | $-15.28M | $-704.33K | $-20.31M | $-137.33K | $-16.34M | $-18.13M | $-12.67M | $-407.00K | $-6.43M | $-8.29M | $-8.44M | $-729.75K | $-12.69M | $-13.01M | $-13.71M | $-10.58M | $-11.52M |
| High Forecast | $-10.48M | $-9.29M | $-7.80M | $-6.55M | $-4.56M | $-3.88M | $-3.19M | $-14.21M | $-5.36M | $-13.25M | $-929.00K | $-15.19M | $-1.98M | $-12.22M | $-704.33K | $-16.25M | $-137.33K | $-13.07M | $-14.51M | $-10.13M | $-407.00K | $-5.14M | $-6.63M | $-6.76M | $-729.75K | $-10.15M | $-10.41M | $-10.97M | $-8.46M | $-9.21M |
| Low Forecast | $-10.48M | $-9.29M | $-7.80M | $-6.55M | $-4.56M | $-3.88M | $-3.19M | $-21.31M | $-5.36M | $-13.25M | $-929.00K | $-22.79M | $-1.98M | $-18.33M | $-704.33K | $-24.38M | $-137.33K | $-19.61M | $-21.76M | $-15.20M | $-407.00K | $-7.72M | $-9.95M | $-10.13M | $-729.75K | $-15.23M | $-15.61M | $-16.45M | $-12.69M | $-13.82M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.97% | 10.24% | - | - | 0.76% | 148.07% | 0.89% | 0.88% | 1.19% | 33.39% | 1.76% | 0.92% | 1.05% | 4.46% | 1.23% | 0.91% | 0.98% | 1.73% | 1.24% |
undefined analysts predict VBIV's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than VBI Vaccines's previous annual EBITDA (undefined) of $NaN.
VBI Vaccines Net Income Forecast
| Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | 1 | - | 1 | - | - | - | - | - | - | - | - | - | - | 6 | 6 | 3 | 3 | 3 | 2 | 2 | 3 | 4 | 7 | 10 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | $-37.42M | $-19.64M | - | - | $-25.65M | $-15.64M | $-15.64M | $-17.67M | $-17.79M | $-15.81M | $-13.40M | $-9.51M | $-8.36M | $-10.88M | $-15.55M | $-13.51M | $-14.91M | $-19.99M | $-15.48M |
| Avg Forecast | $-737.54K | $-1.23M | $-2.21M | $-2.95M | $-3.69M | $-5.41M | $-7.87M | $-18.58M | $-5.41M | $-3.44M | $-53.10M | $-19.87M | $-51.63M | $-16.93M | $-51.63M | $-21.25M | $-46.57M | $-18.11M | $-19.66M | $-14.71M | $-36.83M | $-7.15M | $-9.51M | $-9.75M | $-36.51M | $-13.68M | $-14.11M | $-14.61M | $-11.14M | $-12.30M |
| High Forecast | $-737.54K | $-1.23M | $-2.21M | $-2.95M | $-3.69M | $-5.41M | $-7.87M | $-14.86M | $-5.41M | $-3.44M | $-53.10M | $-15.90M | $-51.63M | $-13.55M | $-51.63M | $-17.00M | $-46.57M | $-14.49M | $-15.73M | $-11.76M | $-36.83M | $-5.72M | $-7.61M | $-7.80M | $-36.51M | $-10.94M | $-11.29M | $-11.68M | $-8.92M | $-9.84M |
| Low Forecast | $-737.54K | $-1.23M | $-2.21M | $-2.95M | $-3.69M | $-5.41M | $-7.87M | $-22.30M | $-5.41M | $-3.44M | $-53.10M | $-23.85M | $-51.63M | $-20.32M | $-51.63M | $-25.50M | $-46.57M | $-21.73M | $-23.59M | $-17.65M | $-36.83M | $-8.58M | $-11.42M | $-11.70M | $-36.51M | $-16.41M | $-16.93M | $-17.53M | $-13.37M | $-14.76M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.88% | 0.38% | - | - | 1.21% | 0.34% | 0.86% | 0.90% | 1.21% | 0.43% | 1.87% | 1.00% | 0.86% | 0.30% | 1.14% | 0.96% | 1.02% | 1.79% | 1.26% |
VBI Vaccines's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. VBIV's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
VBI Vaccines SG&A Forecast
| Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | 1 | - | 1 | - | - | - | - | - | - | - | - | - | - | 6 | 6 | 3 | 3 | 3 | 2 | 2 | 3 | 4 | 7 | 10 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | $13.28M | $15.89M | - | - | $10.93M | $12.53M | $9.69M | $9.37M | $6.75M | $7.13M | $5.56M | $3.90M | $4.06M | $-2.48M | $9.41M | $3.19M | $3.96M | $9.88M | $3.49M |
| Avg Forecast | $299.87M | $265.76M | $223.25M | $187.37M | $130.58M | $110.92M | $91.24M | $81.60M | $153.35M | $379.12M | $26.58M | $23.37M | $56.63M | $36.99M | $20.15M | $3.47M | $3.97M | $5.89M | $13.92M | $14.03M | $11.77M | $9.49M | $18.26M | $18.95M | $21.11M | $20.32M | $14.14M | $12.82M | $52.68M | $6.24M |
| High Forecast | $299.87M | $265.76M | $223.25M | $187.37M | $130.58M | $110.92M | $91.24M | $81.60M | $153.35M | $379.12M | $26.58M | $23.37M | $56.63M | $36.99M | $20.15M | $3.47M | $3.97M | $5.89M | $13.92M | $14.03M | $11.77M | $9.49M | $18.26M | $18.95M | $21.11M | $20.32M | $14.14M | $12.82M | $63.22M | $7.49M |
| Low Forecast | $299.87M | $265.76M | $223.25M | $187.37M | $130.58M | $110.92M | $91.24M | $81.60M | $153.35M | $379.12M | $26.58M | $23.37M | $56.63M | $36.99M | $20.15M | $3.47M | $3.97M | $5.89M | $13.92M | $14.03M | $11.77M | $9.49M | $18.26M | $18.95M | $21.11M | $20.32M | $14.14M | $12.82M | $42.14M | $4.99M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.57% | 0.28% | - | - | 3.15% | 3.15% | 1.65% | 0.67% | 0.48% | 0.61% | 0.59% | 0.21% | 0.21% | -0.12% | 0.46% | 0.23% | 0.31% | 0.19% | 0.56% |
VBI Vaccines's average Quarter SG&A projection for Jul 23 is $26.58M, based on 0 Wall Street analysts, with a range of $26.58M to $26.58M. The forecast indicates a 100.08% rise compared to VBIV last annual SG&A of $13.28M (Mar 23).
VBI Vaccines EPS Forecast
| Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | 1 | - | 1 | - | - | - | - | - | - | - | - | - | - | 6 | 6 | 3 | 3 | 3 | 2 | 2 | 3 | 4 | 7 | 10 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | $-4.34 | $-0.08 | - | - | $-2.98 | $-0.06 | $-0.06 | $-0.07 | $-0.07 | $-0.06 | $-0.06 | $-1.20 | $-1.50 | $-0.10 | $-0.15 | $-0.14 | $-0.15 | $-0.21 | $-0.24 |
| Avg Forecast | $-0.03 | $-0.05 | $-0.09 | $-0.12 | $-0.15 | $-0.22 | $-0.32 | $-0.53 | $-0.22 | $-0.14 | $-2.16 | $-2.27 | $-2.10 | $-2.40 | $-2.10 | $-2.40 | $-2.20 | $-2.10 | $-2.00 | $-1.80 | $-1.74 | $-1.35 | $-1.20 | $-1.88 | $-1.73 | $-3.70 | $-4.20 | $-4.60 | $-0.11 | $-0.16 |
| High Forecast | $-0.03 | $-0.05 | $-0.09 | $-0.12 | $-0.15 | $-0.22 | $-0.32 | $-0.53 | $-0.22 | $-0.14 | $-2.16 | $-2.27 | $-2.10 | $-2.40 | $-2.10 | $-2.40 | $-2.20 | $-2.10 | $-2.00 | $-1.80 | $-1.74 | $-1.35 | $-1.20 | $-1.88 | $-1.73 | $-3.70 | $-4.20 | $-4.60 | $-0.09 | $-0.13 |
| Low Forecast | $-0.03 | $-0.05 | $-0.09 | $-0.12 | $-0.15 | $-0.22 | $-0.32 | $-0.53 | $-0.22 | $-0.14 | $-2.16 | $-2.27 | $-2.10 | $-2.40 | $-2.10 | $-2.40 | $-2.20 | $-2.10 | $-2.00 | $-1.80 | $-1.74 | $-1.35 | $-1.20 | $-1.88 | $-1.73 | $-3.70 | $-4.20 | $-4.60 | $-0.13 | $-0.19 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.92% | 0.04% | - | - | 1.24% | 0.03% | 0.03% | 0.03% | 0.04% | 0.04% | 0.04% | 1.00% | 0.80% | 0.06% | 0.04% | 0.03% | 0.03% | 1.91% | 1.50% |
According to undefined Wall Street analysts, VBI Vaccines's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to VBIV previous annual EPS of $NaN (undefined).
VBI Vaccines Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VBIV | VBI Vaccines | $0.07 | $5.00 | 7042.86% | Strong Buy |
| ALLO | Allogene Therapeutics | $2.96 | $29.00 | 879.73% | Buy |
| GRTS | Gritstone bio | $0.55 | $4.67 | 749.09% | Buy |
| ONTX | Traws Pharma | $1.00 | $7.00 | 600.00% | Buy |
| OCGN | Ocugen | $1.21 | $5.00 | 313.22% | Buy |
| ANVS | Annovis Bio | $8.01 | $23.50 | 193.38% | Buy |
| GOVX | GeoVax Labs | $2.84 | $8.00 | 181.69% | Buy |
| ANIX | Anixa Biosciences | $3.35 | $8.00 | 138.81% | Buy |
| VXRT | Vaxart | $0.99 | $2.00 | 102.02% | Hold |
| BBIO | BridgeBio Pharma | $26.18 | $44.90 | 71.50% | Buy |
| AKRO | Akero Therapeutics | $27.34 | $43.50 | 59.11% | Buy |
| AUPH | Aurinia Pharmaceuticals | $7.03 | $10.75 | 52.92% | Buy |
| ARDX | Ardelyx | $6.31 | $8.75 | 38.67% | Buy |
VBIV Forecast FAQ
Is VBI Vaccines a good buy?
Yes, according to 2 Wall Street analysts, VBI Vaccines (VBIV) is considered a 'Strong Buy'. The rating consensus is based on 1 'Strong Buy' and 0 'Buy' recommendations, accounting for 50.00% of VBIV's total ratings.
What are VBI Vaccines's analysts' financial forecasts?
VBI Vaccines's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $14.48M (high $14.48M, low $14.48M), average EBITDA is $-29.389M (high $-25.837M, low $-32.94M), average net income is $-35.544M (high $-31.828M, low $-39.26M), average SG&A $414.34M (high $414.34M, low $414.34M), and average EPS is $-1.22 (high $-1.22, low $-1.22). VBIV's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $34.12M (high $34.12M, low $34.12M), average EBITDA is $-34.122M (high $-34.122M, low $-34.122M), average net income is $-7.13M (high $-7.13M, low $-7.13M), average SG&A $976.25M (high $976.25M, low $976.25M), and average EPS is $-0.29 (high $-0.29, low $-0.29).
Did the VBIV's actual financial results beat the analysts' financial forecasts?
Based on VBI Vaccines's last annual report (Dec 2022), the company's revenue was $1.08M, which missed the average analysts forecast of $4.1M by -73.59%. Apple's EBITDA was $-81.82M, beating the average prediction of $-38.275M by 113.77%. The company's net income was $-141M, missing the average estimation of $-141M by -0.35%. Apple's SG&A was $56.12M, missing the average forecast of $117.25M by -52.14%. Lastly, the company's EPS was $-0.55, missing the average prediction of $-9 by -93.89%. In terms of the last quarterly report (Mar 2023), VBI Vaccines's revenue was $485K, missing the average analysts' forecast of $817K by -40.64%. The company's EBITDA was $-18.499M, missing the average prediction of $-18.993M by -2.60%. VBI Vaccines's net income was $-37.422M, beating the average estimation of $-19.872M by 88.31%. The company's SG&A was $13.28M, missing the average forecast of $23.37M by -43.17%. Lastly, the company's EPS was $-4.34, beating the average prediction of $-2.265 by 91.61%